With the entire world's attention focused firmly on pulmonary fibrosis in the wake of COVID19 and the landmark INBUILD study dramatically overhauling the ILD drug development landscape, biopharma are finally on the cusp of developing and disseminating life-changing therapeutics for patients suffering with interstitial lung disease.
Built from meticulous research with a faculty of world-renowned lung fibrosis heavyweights including Boehringer Ingelheim, Novartis, Roche, Abbvie, AdAlta and more, the inaugural Interstitial Lung Disease Drug Development Summit is the only industry focused forum giving you access to the ground-breaking research and radical insights you need to re-energize and revolutionize your drug development strategy against the next pulmonary fibrosis frontier.
Across 3 unique days, you will discover how to optimize combination regimes to treat fibrotic lungs to achieve success in your clinical trials, analyze lessons learned from IPF trials to accelerate progress for your novel pulmonary fibrosis therapies and hear how you can utilize the latest research on ILD mechanisms to streamline your drug development strategy and treat SSc-ILD, RA-ILD, Scleroderma, Sjogren's Syndrome, Sarcoidosis and more.
Don't miss the opportunity to join 50+ senior respiratory and fibrosis stakeholders at this unique and comprehensive digital event dedicated to advancing and optimizing your anti-fibrotic drug development beyond IPF
Conference + Workshops Day - Industry: USD 2799.00,
Conference Only - Industry: USD 1999.00,
Workshop Day - Industry: USD 899.00,
Conference + Workshops Day - Academic: USD 1899.00,
Conference Only - Academic: USD 1299.00,
Workshops Day - Academic: USD 699.00
Speakers: Ahmad Nabhan, Postdoctoral Scholar, Genentech, Christina Wenglen, Head of Research, AnaMar, Craig Conoscenti, Medical Expert ILD Respiratory Clinical Development and Medical Affairs, Boehringer Ingelheim, Dinesh Khanna, Professor, University of Michigan, Gisli Jenkins, Professor, University of Nottingham, Jonathan Chung, Professor of Radiology, The University of Chicago Medicine, Karen Moore, Pulmonologist and Postdoctoral Researcher, Erasmus University, Kevin Brown, Professor andChair, Department of Medicine, National Jewish Health, Klaus Kirchgaessler, Group International Medical Director Esbriet, Roche, Mark Hamblin, Assistant Professor, Pulmonary and Critical Care Medicine, University of Kansas Hospital, Marlies Wijsenbeek, Pulmonary Physician, Erasmus University, Maximiliano Tamae Kakazu, Assistant Professor of Medicine, Michigan State, Meghan Clements, Principal Research Scientist, AbbVie, Mick Foley, La Trobe University and Chief Scientific Officer, AdAlta, Monica Bengus, Senior Medical Director, Roche, Preethi Vijayaraj, Principal Scientist – Drug Concept Discovery, Immunology and Respiratory, Boehringer Ingelheim, Rohit Batta, Chief Scientific Officer, Vicore Pharma, Toby Maher, Director, Interstitial Lung Disease Program, USC, Joel Matthews, Director Biomarker Assay Research and Assay Development, Ionis, Majd Mouded, Executive Director for BioMedical Research, Novartis
Time: 09:00 to 15:00